About this trial
The main aim of this study is to evaluate nutritional knowledge and adherence to the Mediterranean diet through the administration of questionnaires in patients with type 2 Diabetes Mellitus belonging to Outpatient Diabetology Service of the Hospital.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
T2DM in nutritional and/or pharmacological euglycemic treatment (metformin, gliptins, gliflozines, incretin mimetics, pioglitazone)
Signing of informed consent
Disqualifiers
Patient with Diabetes Mellitus type 1
Patients with insulin T2DM treated
Trial population
The population of this study consists of patients affected by Type 2 Diabetes belonging to the Diabetology Service of the Hospital
Trial design
Case-only
Prospective
Treatments tested in this trial
administration of questionnaires - Collection of Clinical Parameters - Hand Grip Test
Other interventionThe acquisition of personal and clinical information and the data obtained from the questionnaires will be carried out in conjunction with the usual control visits planned as part of normal clinical practice
Treatment groups
Trial outcomes
Primary outcomes
Average Nutritional Knowledge Score (NK)
Studies often show average scores around 50-60% of correct answers. Knowledge is often measured as a percentage of a total possible score, with a 75% threshold sometimes used to define "basic" or "good" knowledge.
Mediterranean Diet Adherence (AMD) value
High Mediterranean Diet Adherence (AMD) is strongly linked to a reduced risk of developing and progressing to advanced Age-Related Macular Degeneration (AMD), with studies showing 34% to 60% lower risk compared to low adherence. A diet rich in vegetables, fruits, and nuts significantly lowers this risk.
Secondary outcomes
Hand Grip test
muscle strength parameters
fasting blood glucose (mg/dL)
metabolic compensation parameters
glycated haemoglobin (mmol/mol)
metabolic compensation parameters
lipid profile (mg/dL)
metabolic compensation parameters
Sponsors and contacts
Click on the lead sponsor to view all of their trials.